Published in Gastroenterology on April 30, 2013
Early Immunosuppressants in Crohn's Disease (RAPID) | NCT00546546
Reduce Risk for Crohn's Disease Patients (RCT) | NCT02852694
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet (2014) 1.27
Treatment of IBD: where we are and where we are going. Am J Gastroenterol (2014) 1.02
Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated Early with Thiopurines. Dig Dis Sci (2015) 0.80
Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients. Dig Dis Sci (2016) 0.79
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther (2016) 0.79
Could early anti-tumor necrosis factor therapy change the prognosis of Crohn's disease? Intest Res (2014) 0.79
Clinical predictors of thiopurine-related adverse events in Crohn's disease. World J Gastroenterol (2015) 0.78
Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease. BMC Gastroenterol (2014) 0.78
Optimizing post-operative Crohn's disease treatment. Ann Gastroenterol (2014) 0.78
Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn's disease. BMC Gastroenterol (2014) 0.78
Inflammatory bowel disease course in Crohn's disease: is the natural history changing? World J Gastroenterol (2014) 0.78
Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. Clin Exp Immunol (2015) 0.77
Is there still a role for thiopurines in Crohn's disease? Gastroenterology (2013) 0.77
Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers. Inflamm Bowel Dis (2016) 0.75
[News on Azathioprine in IBD]. Z Gastroenterol (2013) 0.75
Shrinking indications for azathioprine in Crohn's disease: a conclusion too premature? Gastroenterology (2014) 0.75
Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience. Intest Res (2015) 0.75
Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. World J Gastroenterol (2016) 0.75
Reply: To PMID 23644079. Gastroenterology (2014) 0.75
Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease. Can J Gastroenterol Hepatol (2014) 0.75
Reply: To PMID 23644079. Gastroenterology (2014) 0.75
Early use of azathioprine in Crohn's disease. Gastroenterology (2014) 0.75
Preventing Collateral Damage in Crohn's Disease: The Lémann Index. J Crohns Colitis (2016) 0.75
Results from early therapy with azathioprine in Crohn's disease. Gastroenterology (2013) 0.75
Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study. Medicine (Baltimore) (2015) 0.75
Anoperineal lesions in Crohn's disease: French recommendations for clinical practice. Tech Coloproctol (2017) 0.75
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 5.31
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis (2002) 4.13
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology (2011) 3.81
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08
Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology (2003) 3.05
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology (2004) 3.04
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 2.91
Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2011) 2.87
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology (2013) 2.78
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology (2005) 2.70
Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology (2003) 2.59
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Capsule endoscopy or push enteroscopy for first-line exploration of obscure gastrointestinal bleeding? Gastroenterology (2006) 2.54
Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol (2008) 2.50
Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med (2011) 2.44
Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol (2008) 2.44
CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest (2007) 2.44
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology (2008) 2.39
Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol (2006) 2.37
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods (2004) 2.25
Molecular inventory of faecal microflora in patients with Crohn's disease. FEMS Microbiol Ecol (2004) 2.21
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med (2006) 2.16
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15
Crohn disease--associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest (2011) 2.10
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood (2007) 2.09
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology (2004) 2.02
Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology (2006) 2.01
Segmental reversal of the small bowel can end permanent parenteral nutrition dependency: an experience of 38 adults with short bowel syndrome. Ann Surg (2012) 2.01
Gastro-esophageal reflux and esophageal motility disorders in morbidly obese patients before and after bariatric surgery. Obes Surg (2007) 1.97
Acute esophageal necrosis: a 1-year prospective study. Gastrointest Endosc (2002) 1.92
Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med (2010) 1.89
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol (2010) 1.82
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol (2009) 1.78
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis (2010) 1.78
Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology (2010) 1.73
A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis (2006) 1.70
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Complete genome sequence of Crohn's disease-associated adherent-invasive E. coli strain LF82. PLoS One (2010) 1.69
Management of inflammatory bowel disease in pregnancy. J Crohns Colitis (2012) 1.69
Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol (2010) 1.64
Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2012) 1.64
Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol (2010) 1.60
Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood (2003) 1.59
Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One (2010) 1.54
Long-term clinical and imaging follow-up of nonoperated branch duct form of intraductal papillary mucinous neoplasms of the pancreas. Pancreas (2012) 1.53
Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol (2008) 1.52